CN101010105A - 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法 - Google Patents

甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法 Download PDF

Info

Publication number: CN101010105A
Authority: CN; China
Prior art keywords: hgh; peg; growth hormone; conjugate; pegylation
Prior art date: 2004-08-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CNA2005800291171A

Other languages

English (en)

Chinese (zh)

Inventor

R·F·芬

N·R·赛格尔

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co

Pharmacia and Upjohn Co LLC

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-31

Filing date

2005-08-25

Publication date

2007-08-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101010105(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-25 Application filed by Upjohn Co filed Critical Upjohn Co

2007-08-01 Publication of CN101010105A publication Critical patent/CN101010105A/zh

Status Pending legal-status Critical Current

Links

108010000521 Human Growth Hormone Proteins 0.000 title claims abstract description 232
102000002265 Human Growth Hormone Human genes 0.000 title claims abstract description 232
239000000854 Human Growth Hormone Substances 0.000 title claims abstract description 223
238000000034 method Methods 0.000 title claims abstract description 36
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title abstract description 162
230000008569 process Effects 0.000 title abstract description 5
229920001223 polyethylene glycol Polymers 0.000 title description 41
239000002202 Polyethylene glycol Substances 0.000 title description 10
238000002360 preparation method Methods 0.000 title description 6
230000012010 growth Effects 0.000 claims abstract description 29
238000011282 treatment Methods 0.000 claims abstract description 29
-1 Polyethylene Polymers 0.000 claims description 15
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
206010056438 Growth hormone deficiency Diseases 0.000 claims description 8
208000020832 chronic kidney disease Diseases 0.000 claims description 8
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
208000020221 Short stature Diseases 0.000 claims description 5
208000011580 syndromic disease Diseases 0.000 claims description 5
208000026928 Turner syndrome Diseases 0.000 claims description 4
125000003275 alpha amino acid group Chemical group 0.000 claims description 4
239000003862 glucocorticoid Substances 0.000 claims description 4
230000004060 metabolic process Effects 0.000 claims description 4
206010029748 Noonan syndrome Diseases 0.000 claims description 3
239000004698 Polyethylene Substances 0.000 claims description 3
208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
208000018773 low birth weight Diseases 0.000 claims description 3
231100000533 low birth weight Toxicity 0.000 claims description 3
229920000573 polyethylene Polymers 0.000 claims description 3
230000009529 traumatic brain injury Effects 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 2
201000010374 Down Syndrome Diseases 0.000 claims description 2
208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
208000001640 Fibromyalgia Diseases 0.000 claims description 2
206010049287 Lipodystrophy acquired Diseases 0.000 claims description 2
208000021642 Muscular disease Diseases 0.000 claims description 2
201000009623 Myopathy Diseases 0.000 claims description 2
208000001132 Osteoporosis Diseases 0.000 claims description 2
208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
206010044688 Trisomy 21 Diseases 0.000 claims description 2
210000001185 bone marrow Anatomy 0.000 claims description 2
238000011161 development Methods 0.000 claims description 2
201000000523 end stage renal failure Diseases 0.000 claims description 2
201000001881 impotence Diseases 0.000 claims description 2
208000006132 lipodystrophy Diseases 0.000 claims description 2
230000002028 premature Effects 0.000 claims description 2
210000000130 stem cell Anatomy 0.000 claims description 2
206010058314 Dysplasia Diseases 0.000 claims 2
230000006320 pegylation Effects 0.000 abstract description 48
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
208000037824 growth disorder Diseases 0.000 abstract description 2
206010012559 Developmental delay Diseases 0.000 abstract 1
150000001299 aldehydes Chemical class 0.000 description 48
229920000642 polymer Polymers 0.000 description 35
102000018997 Growth Hormone Human genes 0.000 description 31
108010051696 Growth Hormone Proteins 0.000 description 31
239000000122 growth hormone Substances 0.000 description 30
108090000623 proteins and genes Proteins 0.000 description 25
239000000203 mixture Substances 0.000 description 23
235000018102 proteins Nutrition 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
241000700159 Rattus Species 0.000 description 21
238000000746 purification Methods 0.000 description 20
239000000126 substance Substances 0.000 description 19
241001465754 Metazoa Species 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 18
239000003814 drug Substances 0.000 description 18
201000010099 disease Diseases 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
230000003203 everyday effect Effects 0.000 description 11
239000000047 product Substances 0.000 description 11
239000000376 reactant Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
229940124597 therapeutic agent Drugs 0.000 description 11
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 9
230000000694 effects Effects 0.000 description 9
238000011160 research Methods 0.000 description 9
239000000523 sample Substances 0.000 description 9
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
102000004142 Trypsin Human genes 0.000 description 8
108090000631 Trypsin Proteins 0.000 description 8
239000000556 agonist Substances 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
235000018977 lysine Nutrition 0.000 description 8
238000012986 modification Methods 0.000 description 8
239000004094 surface-active agent Substances 0.000 description 8
239000012588 trypsin Substances 0.000 description 8
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 7
230000037396 body weight Effects 0.000 description 7
230000008878 coupling Effects 0.000 description 7
238000005859 coupling reaction Methods 0.000 description 7
210000002381 plasma Anatomy 0.000 description 7
238000005932 reductive alkylation reaction Methods 0.000 description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
241001597008 Nomeidae Species 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000002585 base Substances 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
230000021615 conjugation Effects 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
239000013628 high molecular weight specie Substances 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
210000002303 tibia Anatomy 0.000 description 6
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 5
NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 5
239000003957 anion exchange resin Substances 0.000 description 5
238000010241 blood sampling Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
238000004255 ion exchange chromatography Methods 0.000 description 5
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
229920001427 mPEG Polymers 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
239000012614 Q-Sepharose Substances 0.000 description 4
102100022831 Somatoliberin Human genes 0.000 description 4
101710142969 Somatoliberin Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000003729 cation exchange resin Substances 0.000 description 4
238000007385 chemical modification Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000000470 constituent Substances 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
230000007850 degeneration Effects 0.000 description 4
230000036541 health Effects 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000011347 resin Substances 0.000 description 4
229920005989 resin Polymers 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
238000002965 ELISA Methods 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 3
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
125000001118 alkylidene group Chemical group 0.000 description 3
229960002938 bexarotene Drugs 0.000 description 3
230000031018 biological processes and functions Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000011210 chromatographic step Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000012634 fragment Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000037356 lipid metabolism Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 3
150000003141 primary amines Chemical class 0.000 description 3
230000008521 reorganization Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000001542 size-exclusion chromatography Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
239000003643 water by type Substances 0.000 description 3
229920003169 water-soluble polymer Polymers 0.000 description 3
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010008190 Cerebrovascular accident Diseases 0.000 description 2
206010013883 Dwarfism Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
229920001503 Glucan Polymers 0.000 description 2
102100020948 Growth hormone receptor Human genes 0.000 description 2
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229940122355 Insulin sensitizer Drugs 0.000 description 2
102100037852 Insulin-like growth factor I Human genes 0.000 description 2
102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 2
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
239000004141 Sodium laurylsulphate Substances 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
238000005571 anion exchange chromatography Methods 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
229910000085 borane Inorganic materials 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000034994 death Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229940063135 genotropin Drugs 0.000 description 2
125000003827 glycol group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229960000367 inositol Drugs 0.000 description 2
230000002608 insulinlike Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000001983 lactogenic effect Effects 0.000 description 2
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
238000012510 peptide mapping method Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920000233 poly(alkylene oxides) Polymers 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
239000002861 polymer material Substances 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
238000012827 research and development Methods 0.000 description 2
229960004586 rosiglitazone Drugs 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
238000013223 sprague-dawley female rat Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
229940099419 targretin Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 1
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 1
WURGZWOTGMLDJP-ZCYANPAGSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl-[(2r)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound C([C@H](C(=O)NC)N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C1=CC=CC=C1 WURGZWOTGMLDJP-ZCYANPAGSA-N 0.000 description 1
ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 description 1
LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
KCEFVYIWOQSJCH-LMOVPXPDSA-N 2-[4-[2-[[(2r)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]acetic acid;hydrochloride Chemical compound Cl.C([C@H](O)C=1C=CC=CC=1)NCCOC1=CC=C(CC(O)=O)C=C1 KCEFVYIWOQSJCH-LMOVPXPDSA-N 0.000 description 1
CCTREOMTIFSZAU-OGFXRTJISA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;5-[(3r)-dithiolan-3-yl]pentanoic acid Chemical compound OCC(N)(CO)CO.OC(=O)CCCC[C@@H]1CCSS1 CCTREOMTIFSZAU-OGFXRTJISA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
102100033367 Appetite-regulating hormone Human genes 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
229940122815 Aromatase inhibitor Drugs 0.000 description 1
239000007992 BES buffer Substances 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229940123208 Biguanide Drugs 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000004860 Dipeptidases Human genes 0.000 description 1
108090001081 Dipeptidases Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
101710115821 Flavin reductase (NADPH) Proteins 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
102100033299 Glia-derived nexin Human genes 0.000 description 1
101710183811 Glia-derived nexin Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
206010021067 Hypopituitarism Diseases 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
102100025947 Insulin-like growth factor II Human genes 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
229940126033 PPAR agonist Drugs 0.000 description 1
102000000536 PPAR gamma Human genes 0.000 description 1
108010016731 PPAR gamma Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
102000004576 Placental Lactogen Human genes 0.000 description 1
108010003044 Placental Lactogen Proteins 0.000 description 1
239000000381 Placental Lactogen Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102100024819 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
108010068542 Somatotropin Receptors Proteins 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
BQODPTQLXVVEJG-UHFFFAOYSA-N [O].C=C Chemical group [O].C=C BQODPTQLXVVEJG-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
229960003526 acipimox Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
229940062328 actos Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229950004810 atamestane Drugs 0.000 description 1
PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
229940062310 avandia Drugs 0.000 description 1
230000000680 avirulence Effects 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical class C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
150000003851 azoles Chemical class 0.000 description 1
229920005601 base polymer Polymers 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 1
229950004826 capromorelin Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012501 chromatography medium Substances 0.000 description 1
208000037516 chromosome inversion disease Diseases 0.000 description 1
229960002174 ciprofibrate Drugs 0.000 description 1
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
108010018927 conglutinin Proteins 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
125000001162 cycloheptenyl group Chemical class C1(=CCCCCC1)* 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 1
229960001894 detomidine Drugs 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229960003913 econazole Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229950001583 examorelin Drugs 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229950011548 fadrozole Drugs 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
229960004421 formestane Drugs 0.000 description 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
108010070965 hexarelin Proteins 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000001596 intra-abdominal fat Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000010829 isocratic elution Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
239000012731 long-acting form Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
108010000594 mecasermin Proteins 0.000 description 1
229960001311 mecasermin Drugs 0.000 description 1
HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
229960002140 medetomidine Drugs 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
LKQUCICFTHBFAL-UHFFFAOYSA-N n-benzylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NCC1=CC=CC=C1 LKQUCICFTHBFAL-UHFFFAOYSA-N 0.000 description 1
229950001628 netoglitazone Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
229940063149 nutropin Drugs 0.000 description 1
230000011164 ossification Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
239000003016 pheromone Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229960000208 pralmorelin Drugs 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
229960002290 pyridostigmine Drugs 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
108010077161 rat insulin-like growth factor-1 Proteins 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
230000011514 reflex Effects 0.000 description 1
229950005713 reglitazar Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
238000005070 sampling Methods 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 1
229960002758 sermorelin Drugs 0.000 description 1
230000004096 skeletal muscle tissue growth Effects 0.000 description 1
210000002356 skeleton Anatomy 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
108700031632 somatrem Proteins 0.000 description 1
229960003259 somatrem Drugs 0.000 description 1
229960004532 somatropin Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000012622 synthetic inhibitor Substances 0.000 description 1
229950008131 tabimorelin Drugs 0.000 description 1
108010064878 tabimorelin Proteins 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
229960001844 tubocurarine Drugs 0.000 description 1
HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
238000012795 verification Methods 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
229960001771 vorozole Drugs 0.000 description 1
XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pregnancy & Childbirth (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CNA2005800291171A 2004-08-31 2005-08-25 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法 Pending CN101010105A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60594504P	2004-08-31	2004-08-31
US60/605,945		2004-08-31

Publications (1)

Publication Number	Publication Date
CN101010105A true CN101010105A (zh)	2007-08-01

Family

ID=35708806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CNA2005800291171A Pending CN101010105A (zh)	2004-08-31	2005-08-25	甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法

Country Status (24)

Country	Link
EP (1)	EP1789092A2 (pt)
JP (1)	JP2008511610A (pt)
KR (1)	KR20070042567A (pt)
CN (1)	CN101010105A (pt)
AP (1)	AP2007003919A0 (pt)
AR (1)	AR050851A1 (pt)
AU (1)	AU2005278903A1 (pt)
BR (1)	BRPI0515118A (pt)
CA (1)	CA2577999A1 (pt)
CR (1)	CR8942A (pt)
EA (1)	EA200700380A1 (pt)
EC (1)	ECSP077281A (pt)
GT (1)	GT200500235A (pt)
IL (1)	IL181085A0 (pt)
MA (1)	MA28908B1 (pt)
MX (1)	MX2007002441A (pt)
NL (1)	NL1029828C2 (pt)
NO (1)	NO20071322L (pt)
PE (1)	PE20060654A1 (pt)
TN (1)	TNSN07078A1 (pt)
TW (1)	TW200621291A (pt)
UY (1)	UY29088A1 (pt)
WO (1)	WO2006024953A2 (pt)
ZA (1)	ZA200701802B (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101831067A (zh) *	2010-05-31	2010-09-15	王二新	聚乙二醇脂类缀合物及其在制备药物中的应用
CN102367290A (zh) *	2011-04-26	2012-03-07	刘超	链官能化的多级支化聚乙二醇及其合成方法
WO2014110867A1 (zh) *	2013-01-17	2014-07-24	厦门赛诺邦格生物科技有限公司	一种单一官能化的支化聚乙二醇及其修饰的生物相关物质

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
CA2296770A1 (en)	1997-07-14	1999-01-28	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins
IL144259A0 (en)	1999-01-14	2002-05-23	Bolder Biotechnology Inc	Methods for making proteins containing free cysteine residues
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) *	2006-03-13	2007-09-19	Siegfried Ltd.	Di-polymer protein conjugates and processes for their preparation
US20090117077A1 (en) *	2006-05-12	2009-05-07	Dong-A Pharm. Co., Ltd.	Polyethylene glycol-interferon alpha conjugate
JP2008069073A (ja) *	2006-09-12	2008-03-27	Yokohama Tlo Co Ltd	ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko)	2006-11-17	2011-11-04	동아제약주식회사	폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es)	2007-08-16	2009-01-02	Pharmaessentia Corp	Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
RU2483081C2 (ru) *	2008-07-23	2013-05-27	Ханми Сайенс Ко.,Лтд.,Kr	Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
MX2011001167A (es)	2008-07-31	2011-04-12	Pharmaessentia Corp	Conjugados peptido-polimero.
SG195531A1 (en) *	2008-10-10	2013-12-30	Bionic Ear Inst	Biodegradable polymer - bioactive moiety conjugates
US8535655B2 (en)	2008-10-10	2013-09-17	Polyactiva Pty Ltd.	Biodegradable polymer—bioactive moiety conjugates
SI2340271T1 (sl)	2008-10-10	2019-08-30	Polyactiva Pty Ltd.	Konjugati polimer-bioaktivnega sredstva
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
ES2610356T3 (es)	2009-02-03	2017-04-27	Amunix Operating Inc.	Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en)	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
US8841249B2 (en)	2009-08-06	2014-09-23	Novo Nordisk A/S	Growth hormones with prolonged in-vivo efficacy
EP2446898A1 (en)	2010-09-30	2012-05-02	Laboratorios Del. Dr. Esteve, S.A.	Use of growth hormone to enhance the immune response in immunosuppressed patients
CN104877127B (zh)	2015-06-23	2017-11-10	厦门赛诺邦格生物科技股份有限公司	一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
CA2964390A1 (en)	2014-11-06	2016-05-12	Pharmaessentia Corporation	Dosage regimen for pegylated interferon
ES2905105T3 (es)	2017-12-29	2022-04-07	Hoffmann La Roche	Procedimiento para proporcionar una composición de proteína PEGilada
EP3731871B1 (en) *	2017-12-29	2023-10-04	F. Hoffmann-La Roche AG	Process for providing pegylated protein composition
SI3731873T1 (sl) *	2017-12-29	2022-05-31	F. Hoffmann-La Roche Ag	Postopek za zagotavljanje sestavka PEGiliranih beljakovin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2147192A (en) *	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
JP3092531B2 (ja) *	1996-11-05	2000-09-25	日本油脂株式会社	コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
CA2296770A1 (en) *	1997-07-14	1999-01-28	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins
JP3921781B2 (ja) *	1998-02-12	2007-05-30	日本油脂株式会社	カルボキシル基含有ポリオキシアルキレン化合物
IL144259A0 (en) *	1999-01-14	2002-05-23	Bolder Biotechnology Inc	Methods for making proteins containing free cysteine residues
JP2005525302A (ja) *	2001-11-20	2005-08-25	ファルマシア・コーポレーション	化学的に修飾されたヒト成長ホルモンコンジュゲート
EP1546235B1 (en) *	2002-09-09	2021-10-20	Nektar Therapeutics	Water-soluble polymer alkanals
JP4412461B2 (ja) *	2002-11-20	2010-02-10	日油株式会社	修飾された生体関連物質、その製造方法および中間体
WO2004060406A2 (en) *	2002-12-31	2004-07-22	Nektar Therapeutics Al, Corporation	Polymeric reagents comprising a ketone or a related functional group
EP3593820A1 (en) *	2003-05-23	2020-01-15	Nektar Therapeutics	Peg derivatives containing two peg chains

2005
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/es unknown
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en active Application Filing
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/ja active Pending
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/pt not_active IP Right Cessation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/xx unknown
- 2005-08-25 EA EA200700380A patent/EA200700380A1/ru unknown
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/zh active Pending
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/ko not_active Application Discontinuation
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/es not_active Application Discontinuation
- 2005-08-29 UY UY29088A patent/UY29088A1/es not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/es unknown
- 2005-08-30 NL NL1029828A patent/NL1029828C2/nl not_active IP Right Cessation
- 2005-08-30 TW TW094129583A patent/TW200621291A/zh unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/es unknown
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/es not_active Application Discontinuation
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/es unknown
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/fr unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/fr unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/xx unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/no not_active Application Discontinuation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101831067A (zh) *	2010-05-31	2010-09-15	王二新	聚乙二醇脂类缀合物及其在制备药物中的应用
CN102367290A (zh) *	2011-04-26	2012-03-07	刘超	链官能化的多级支化聚乙二醇及其合成方法
CN102367290B (zh) *	2011-04-26	2013-05-08	厦门赛诺邦格生物科技有限公司	链官能化的多级支化聚乙二醇及其合成方法
WO2014110867A1 (zh) *	2013-01-17	2014-07-24	厦门赛诺邦格生物科技有限公司	一种单一官能化的支化聚乙二醇及其修饰的生物相关物质

Also Published As

Publication number	Publication date
NL1029828A1 (nl)	2006-03-01
BRPI0515118A (pt)	2008-07-01
PE20060654A1 (es)	2006-08-12
EP1789092A2 (en)	2007-05-30
TW200621291A (en)	2006-07-01
MA28908B1 (fr)	2007-10-01
UY29088A1 (es)	2006-03-31
WO2006024953A2 (en)	2006-03-09
AP2007003919A0 (en)	2007-02-28
MX2007002441A (es)	2007-05-04
AR050851A1 (es)	2006-11-29
ECSP077281A (es)	2007-03-29
AU2005278903A1 (en)	2006-03-09
IL181085A0 (en)	2007-07-04
JP2008511610A (ja)	2008-04-17
WO2006024953A3 (en)	2007-01-18
GT200500235A (es)	2006-03-21
CA2577999A1 (en)	2006-03-09
TNSN07078A1 (fr)	2008-06-02
KR20070042567A (ko)	2007-04-23
CR8942A (es)	2007-08-16
NL1029828C2 (nl)	2006-10-20
NO20071322L (no)	2007-05-29
ZA200701802B (en)	2008-08-27
EA200700380A1 (ru)	2007-10-26

Legal Events

Date	Code	Title	Description
2007-08-01	C06	Publication
2007-08-01	PB01	Publication
2007-09-26	C10	Entry into substantive examination
2007-09-26	SE01	Entry into force of request for substantive examination
2008-01-25	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1104913 Country of ref document: HK
2010-07-14	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2010-07-14	WD01	Invention patent application deemed withdrawn after publication	Open date: 20070801
2014-03-21	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1104913 Country of ref document: HK

Publication	Publication Date	Title
CN101010105A (zh)	2007-08-01	甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法
EP1715887B1 (en)	2007-06-20	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and use thereof
EP2279007B1 (en)	2016-05-18	Pegylated recombinant human growth hormone compounds
JP3628333B2 (ja)	2005-03-09	ヒト成長ホルモン変異体
KR20050044858A (ko)	2005-05-13	화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
US20030171285A1 (en)	2003-09-11	Chemically-modified human growth hormone conjugates
US20040127417A1 (en)	2004-07-01	N-terminally monopegylated human growth hormone conjugates and process for their preparation
US20040038892A1 (en)	2004-02-26	Chemically-modified human growth hormone conjugates
EP2113256A1 (en)	2009-11-04	PEGylated rhGH compounds
Finn	2009	PEGylation of human growth hormone: strategies and properties
MXPA06008888A (en)	2007-04-10	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof